[Federal Register Volume 64, Number 137 (Monday, July 19, 1999)] [Notices] [Page 38685] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 99-18376] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Glycoprotein Hormone Superagonists
Agency
National Institutes of Health, Public Health Service, DHHS.
Action
Notice.
-----------------------------------------------------------------------
Summary
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license worldwide to practice the invention embodied in: U.S. Patent Application Serial No. 09/185,408 filed May 6, 1996 entitled ``Glycoprotein Hormone Superagonists'', to University of Maryland, having a place of business in Baltimore, Maryland. The United States of America is the assignee of the patent rights in this invention.
Dates
Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before September 17, 1999 will be considered.
Addresses
Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Charles Maynard, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-7056, ext. 243; Facsimile: (301) 402-0220; e-mail: [email protected]
Supplementary Information
This invention relates generally to modified glycoprotein hormones and specifically to modifications to a human glycoprotein, which create superagonist activity. Glycoprotein hormones comprise a family of hormones, which are structurally related heterodimers consisting of a species common sub-unit and a distinct sub-unit that confers the biological activity for each hormone. However, this invention is not limited to specific hormones, specific subjects such as humans as well as non-humans mammals, specific amino acids, specific clinical conditions, specific analogs, or specific methods. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.
Dated: July 12, 1999. Jack Spiegel, Director, Division of Technology Development and Transfer, Office of Technology Transfer. [FR Doc. 99-18376 Filed 7-16-99; 8:45 am] BILLING CODE 4140-01-M